Skip to main content

Angeles Alvarez Secord, MD

Angeles Secord, MD
Professor of Obstetrics and Gynecology
Campus Mail: 25172 Morris Bldg, Durham, NC 27710
Phone: (919) 684-3765

My primary research interest has focused on angiogenesis, molecular signatures, clinical trial development, and ovarian cancer. My fundamental goal is to develop a strong translational research program at Duke University in the Gynecologic Oncology Division where knowledge we glean from our basic science research can be incorporated into our clinical trial program. Specifically on anti-angiogenic therapy and molecular tumor signatures to direct therapy in patients with ovarian cancer to determine if a strategy that incorporates both clinical and genomic information can improve clinical outcome, minimize unnecessary toxicity, and impact positively on quality of life.
In addition I am interested in robotic-assisted laparoscopic surgery for women with endometrial, ovarian, and cervical cancers as well as for benign gynecologic conditions.

Education and Training

  • Resident, Obstetrics & Gynecology, Duke University, 1994 - 1998
  • M.D., University of Washington, 1994


  • Duke University Medical Center, Masters of Health Sciences in Clinical Research, 2005-2011


Dr. Secord's research interests include elucidating the underlying genetic biology of angiogenesis in ovarian cancer, innovative clinical trial design, development of novel targeted therapies for personalized medicine, identification of biomarkers to direct anti-neoplastic therapy, and the incorporation of patient-reported outcomes in clinical trials. She has studied the regulation of angiogenesis in ovarian cancer for approximately 20 years and has recently extended our research to include the immunophenotype of the tumor microenvironment. 


Selected Grants and Awards


Siamakpour-Reihani, S, Owzar, K, Jiang, C, Turner, T, Deng, Y, Bean, SM, Horton, JK, Berchuck, A, Marks, JR, Dewhirst, MW, and Alvarez Secord, A. "Prognostic significance of differential expression of angiogenic genes in women with high-grade serous ovarian carcinoma." Gynecologic oncology 139, no. 1 (October 2015): 23-29.

Full Text

Previs, R, III, LCA, Coleman, RL, Herzog, TJ, Krivak, TC, Brower, SL, Tian, C, and Secord, AA. "Evaluation of in vitro chemoresponse profiles in women with Type I and Type II epithelial ovarian cancers: An observational study ancillary analysis." GYNECOLOGIC ONCOLOGY 138, no. 2 (August 2015): 267-271.

Full Text

Previs, R, Leath, CA, Coleman, RL, Herzog, TJ, Krivak, TC, Brower, SL, Tian, C, and Secord, AA. "Evaluation of in vitro chemoresponse profiles in women with Type I and Type II epithelial ovarian cancers: An observational study ancillary analysis." Gynecologic Oncology 138, no. 2 (August 2015): 267-271.

Full Text

Zhang, C, Roque, D, Ehrisman, JA, DiSanto, N, Broadwater, G, Doll, KM, Gehrig, PA, Secord, AA, and Havrilesky, LJ. "Lumbee Native American ancestry and the incidence of aggressive histologic subtypes of endometrial cancer." Gynecologic Oncology Reports 13 (August 2015): 49-52.

Full Text

Secord, AA, Coleman, RL, Havrilesky, LJ, Abernethy, AP, Samsa, GP, and Cella, D. "Patient-reported outcomes as end points and outcome indicators in solid tumours." Nature Reviews. Clinical Oncology 12, no. 6 (June 2015): 358-370. (Review)

Full Text

Kushnir, CL, Angarita, AM, Havrilesky, LJ, Thompson, S, Spahlinger, D, Sinno, AK, Tanner, EJ, Secord, AA, Roche, KL, Stone, RL, and Fader, AN. "Selective cardiac surveillance in patients with gynecologic cancer undergoing treatment with pegylated liposomal doxorubicin (PLD)." Gynecologic oncology 137, no. 3 (June 2015): 503-507.

Full Text

Aghajanian, C, Filiaci, VL, Dizon, DS, Carlson, J, Powell, MA, Secord, AA, Tewari, KS, Bender, D, O'Malley, DM, Stuckey, A, Rotmensch, J, Levine, DA, Lankes, HA, and Moore, KN. "A randomized phase II study of paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus and ixabepilone/carboplatin/bevacizumab as initial therapy for measurable stage III or IVA, stage IVB or recurrent endometrial cancer, GOG-86P." May 20, 2015.


Lopez-Acevedo, M, Buchanan, AH, Secord, AA, Lee, PS, Fountain, C, Myers, ER, Cohn, DE, Reed, SD, and Havrilesky, LJ. "Cost comparison among different genetic testing strategies in women with epithelial ovarian cancer.": Elsevier BV, April 2015.

Full Text

Fuh, KC, Secord, AA, Bevis, KS, Huh, WK, Blansit, K, Rosenfeld, E, Hu, L, Previs, RA, Gardner, AB, Kapp, DS, and Chan, JK. "Disease stabilization versus response after bevacizumab treatment in recurrent ovarian cancer: How do we determine clinical efficacy?.": Elsevier BV, April 2015.

Full Text

Davidson, BA, Mannschreck, DB, Broadwater, G, Lopez-Acevedo, M, Lee, PS, Havrilesky, LJ, Valea, FA, Berchuck, A, and Secord, AA. "Findings at laparoscopy, not debulking status, are associated with survival in advanced stage ovarian cancer after neoadjuvant chemotherapy.": Elsevier BV, April 2015.

Full Text